Reckitt Benckiser stock hits a 52-week high as £1.6bn special dividend clock starts

Reckitt Benckiser stock hits a 52-week high as £1.6bn special dividend clock starts

London, Jan 10, 2026, 08:36 GMT — Market closed

  • Reckitt shares ended Friday up 0.1% at 6,176 pence after touching a 12-month high of 6,262 pence
  • Investors are tracking a proposed 235 pence special dividend and a 24-for-25 share consolidation in coming weeks
  • Next dates in focus include a shareholder vote on Jan. 27 and full-year results on March 5

Reckitt Benckiser Group plc shares closed Friday up 0.1% at 6,176 pence after touching a 12-month high of 6,262 pence, as investors weighed an imminent cash return and the mechanics around it. The stock is up about 3.2% over the past week, data showed. (Hargreaves Lansdown)

The market is shut for the weekend, but the timetable is the story now. A one-off payout and an accompanying share consolidation can shift the quoted price in early February even if the underlying value is unchanged, and that tends to pull in short-term positioning.

Reckitt said this week it planned a special dividend — a one-off payout on top of regular dividends — of 235 pence a share, alongside a 24-for-25 share consolidation, which cuts the share count by about 4% while lifting the price per share to offset the distribution. The company’s circular sets a shareholder vote for Jan. 27 and says the shares will be marked “ex-special dividend” on Feb. 2, meaning buyers from that point are no longer entitled to the payout; the cash is due on Feb. 20, subject to approval. (Investegate)

The group has also kept buying stock. Reckitt said it repurchased 49,000 shares on Jan. 8 at a volume-weighted average price of 6,112.19 pence, and will hold the shares in treasury. (Investegate)

The climb has not happened in a vacuum. On Thursday, Reckitt rose 1.92% while the FTSE 100 edged lower, and the stock printed a fresh 52-week high in that session, according to market data. (MarketWatch)

The cash return follows the end-2025 completion of Reckitt’s sale of a majority stake in its Essential Home business to Advent International, while retaining a 30% stake. Chief executive Kris Licht called the deal “a major step forward” as the group shifts toward a “simpler” consumer health and hygiene business. (Reckitt)

But the near-term setup is not risk-free. Shareholder approval is still required, and the share price normally adjusts when a stock goes ex-dividend, even when a consolidation is designed to smooth the move. A wobble in broader equities could also drown out the corporate-action trade.

After the vote and the early-February reset, investors will turn to operations again: Reckitt is due to report full-year results on March 5. (Reckitt)

Stock Market Today

  • Can India's Budget Stem $23 Billion Foreign Investor Outflow? Market Expectations
    January 31, 2026, 10:14 PM EST. Foreign institutional investors (FIIs) have withdrawn $23 billion from Indian equities since 2025, intensifying pressure on Finance Minister Nirmala Sitharaman's Budget. The rupee's depreciation and subdued post-tax returns have made Indian stocks less attractive compared to safer assets abroad. Experts highlight potential tax relief for foreign portfolio investors (FPIs) as a key Budget highlight, which could support equity inflows. Jefferies considers such relief a positive but not guaranteed. Morgan Stanley suggests broader reforms, including easing buyback taxes and enhancing Gift City incentives. Analysts urge cutting the 12.5% long-term capital gains tax for foreign investors and boosting earnings growth at India Inc to justify high valuations. Overall, investors seek measures balancing tax benefits with corporate earnings to halt the outflow and attract sustainable foreign investments.
BP stock jumps with oil prices as buyback rolls on — here’s what investors watch next
Previous Story

BP stock jumps with oil prices as buyback rolls on — here’s what investors watch next

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results
Next Story

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

Go toTop